ReviewThe AAPS journal2013
Strategic applications of gene expression: from drug discovery/development to bedside.
Review in The AAPS journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- GANomics: bridging legacy and modern transcriptomic platforms for clinical applications.NPJ genomic medicine · 2026Article
- MVGAE: A Multi-View Graph Auto-Encoder Model for Drug Prediction of Non-Small Cell Lung Cancer Based on Synthetic Lethality.Current issues in molecular biology · 2026Article
- Semi-supervised Bayesian integration of multiple spatial proteomics datasets.PLoS computational biology · 2025Article
- GETgene-AI: a framework for prioritizing actionable cancer drug targets.Frontiers in systems biology · 2025Article
- Genomic strategies for drug repurposing.Journal of the Egyptian National Cancer Institute · 2024Review
- Characteristics of RNA Stabilizer RNApro for Peripheral Blood Collection.Diagnostics (Basel, Switzerland) · 2024Article
- Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer.iScience · 2023Article
- Bibliometric analysis of real-time PCR-based pathogen detection in plant protection research: a comprehensive study.Frontiers in plant science · 2023Article
- Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors.BMC cancer · 2022Article
- Consensus clustering for Bayesian mixture models.BMC bioinformatics · 2022Article
- Influence of storage conditions of small volumes of blood on immune transcriptomic profiles.BMC research notes · 2020Article
- Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn's Disease.Inflammatory bowel diseases · 2018Article
- In silico prediction of novel therapeutic targets using gene-disease association data.Journal of translational medicine · 2017Article
- Time Course Expression Analysis of 1[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole Induction of Cytoprotection in Human Endothelial Cells.Gene regulation and systems biology · 2017Article
- Next-Generation Sequencing: The Translational Medicine Approach from "Bench to Bedside to Population".Medicines (Basel, Switzerland) · 2016Review
- Personalized radiotherapy: concepts, biomarkers and trial design.The British journal of radiology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gene expression is useful for identifying the molecular signature of a disease and for correlating a pharmacodynamic marker with the dose-dependent cellular responses to exposure of a drug. Gene expression offers utility to guide drug discovery by illustrating engagement of the desired cellular pathways/networks, as well as avoidance of acting on the toxicological pathways. Successful employment of gene-expression signatures in the later stages of drug development depends on their linkage to clinically meaningful phenotypic characteristics and requires a biologically meaningful mechanism combined with a stringent statistical rigor. Much of the success in clinical drug development is hinged on predefining the signature genes for their fitness for purposes of application. Specific examples are highlighted to illustrate the breadth and depth of the potential utility of gene-expression signatures in drug discovery and clinical development to targeted therapeutics at the bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.